Merck & Co. has acquired Verona Pharma for $10 billion in a deal designed to expand the pharma giant’s portfolio of cardio-pulmonary disease treatments. In a step toward virtual cell benchmarking, the Arc Institute has launched the Virtual Cell Challenge to evaluate the ability of transcriptome AI models to generalize to new cell contexts for therapeutic applications. Fujifilm rebrands life science companies to position itself as a drug development leader. Additionally, AAV-OTOF gene therapy shows promise in restoring hearing loss while a new proteomics tool gleams insight into telomere repair. We wrap up our episode with highlights from BIO 2025, as FDA Commissioner Martin Makary, MD, shared his vision for a “New FDA” focused on accelerating drug applications, industry partnerships, and applying AI.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
Merck to Acquire Verona Pharma for $10B, Adding Fast-Growing COPD Drug
By Alex Philippidis, GEN Edge, July 9, 2025
Arc Institute Launces Virtual Cell Challenge to Accelerate AI Model Development
By Fay Lin, PhD, GEN Edge, June 26, 2025
End-to-End: Fujifilm Rebrands Life Sciences Companies, Positioning Itself as Drug Development Cycle Leader
By Alex Philippidis, GEN Edge, July 8, 2025
AAV-OTOF Gene Therapy Trial Restores Hearing in Both Children and Adults
By GEN, July 7, 2025
Proteomics Tool Sheds Light on Cancer Cells’ Telomere Repair Tactics
By GEN, July 7, 2025
Makary Calls for “New FDA” at BIO; Defends Agency’s Spring Job Cuts
By Alex Philippidis, GEN Edge, June 18, 2025
Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions”
By Kevin Davies, PhD, and Alex Philippidis, GEN Edge, June 5, 2025
Behind the Breakthroughs Podcast
Hosted by Jonathan D. Grinstein, PhD
The post Merck Acquires Verona, Virtual Cell Challenge, Gene Therapy Restores Hearing appeared first on GEN – Genetic Engineering and Biotechnology News.
